Screener
Rigel Pharmaceuticals RIGL Contingent liabilities
Contingent liabilities at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Accounts payable | $4,486 | $7,191 |
| Accrued compensation | 6,009 | 11,914 |
| Accrued research and development | 5,742 | 5,524 |
| Acquisition-related liabilities | 5,000 | 5,000 |
| Revenue reserves and refund liability | 28,080 | 27,716 |
| Loans payable, net, current portion | 29,865 | 29,812 |
| Other accrued liabilities | 9,674 | 11,466 |
| Lease liabilities, current portion | 636 | 614 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's contingent liabilities?
- Rigel Pharmaceuticals (RIGL) reported contingent liabilities of $5M in Q1 2026.
- What does contingent liabilities mean?
- This represents the fair value of potential future payments to sellers of acquired assets or businesses, contingent upon the achievement of specific performance milestones. It reflects the financial risk associated with integration and the potential for future cash outflows based on operational success. Investors track this to understand the company's long-term obligations tied to inorganic growth strategies.
Ask your AI about Rigel Pharmaceuticals's contingent liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude